logo
Anthem Biosciences shares list at 27% premium, miss IPO GMP forecasts

Anthem Biosciences shares list at 27% premium, miss IPO GMP forecasts

Anthem Biosciences IPO listing, Anthem Biosciences share price: Shares of innovation-driven and technology-focused company Anthem Biosciences made a solid D-Street debut on Monday, July 21, following the completion of its initial public offering (IPO). The company's shares listed at ₹723.10 per share on the BSE, reflecting a premium of ₹153.10 or 26.86 per cent over the issue price of ₹570 per share.
On the National Stock Exchange (NSE), Anthem Biosciences shares listed at a mildly lower premium of ₹153.05 or 26.85 per cent at ₹723.05 per share over the issue price.
Anthem Biosciences IPO listing came below the grey market estimate. Ahead of their debut on the bourses, the unlisted shares of Anthem Biosciences were exchanging hands at around ₹749 per share, reflecting a grey market premium (GMP) of ₹179 per share or nearly 31.40 per cent over the issue price of ₹570 per share, showed the sources that track unofficial market activities.
Anthem Biosciences IPO details
Anthem Biosciences IPO comprised entirely an offer-for-sale (OFS) with promoters and shareholders divesting up to 59.6 million equity shares estimated to be worth ₹3,395 crore. The public issue was offered at a price band of ₹540–570 with a lot size of 26 shares, and was open for subscription from July 14, 2025, till July 16, 2025.
Anthem Biosciences received strong demand from investors for its public issue as it got oversubscribed by 63.86 times. The demand was led by the qualified institutional buyers (QIBs), who bid for 182.65 times the category reserved for them, showed the NSE data.
Anthem Biosciences, as outlined in its red herring prospectus (RHP), will not use any proceeds from the public issue, and it will be given to the promoters and shareholders selling their stakes through the OFS.
About Anthem Biosciences
Incorporated in 2006, Anthem Biosciences is a contract research, development, and manufacturing organisation (CRDMO) serving global customers. The company manufactures specialised fermentation-based APIs, including probiotics and enzymes. Anthem Biosciences has a diverse customer base, including biotech firms and large pharmaceutical companies, spanning over 44 countries. As of September 2024, the company had 196 projects and over 425 customers in its CRDMO business. The company holds one patent in India and seven overseas, with 24 pending global patent applications.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ICL Fincorp's new NCD issue opens on July 31, 2025, offering effective yield up to 12.62%
ICL Fincorp's new NCD issue opens on July 31, 2025, offering effective yield up to 12.62%

New Indian Express

time2 hours ago

  • New Indian Express

ICL Fincorp's new NCD issue opens on July 31, 2025, offering effective yield up to 12.62%

ICL Fincorp is proud to announce the launch of its latest public issue of Secured Redeemable Non-Convertible Debentures (NCDs), opening on 31st July 2025. With an effective yield of up to 12.62%, this offering presents an attractive and secure investment opportunity for those seeking flexible tenures. Following the remarkable response to our previous NCD issues, which were oversubscribed, we are truly honoured by the trust and confidence placed in us by our valued investors. This continued support inspires us to deliver even more robust financial solutions tailored to the evolving needs of our customers. The NCD issue will remain open until 13th August 2025 and is rated CRISIL BBB- /STABLE. Each NCD carries a face value of ₹1,000,and the issue offers 10 schemes with ten options (10 ISINs), with interest rates ranging from10.50% to 12.00%. The minimum application amount is ₹10,000, making it accessible to a broad spectrum of investors. Proceeds from this issue will be strategically deployed to support ICL Fincorp's growth initiatives and further enhance the quality of services offered to our customers and stakeholders across India. This step reaffirms our commitment to delivering reliable, innovative and customer-centric financial solutions. With a legacy of 34 years, ICL Fincorp continues to serve as a trusted financial partner under the visionary leadership of CMD, Adv. K.G. Anilkumar. Our growing presence spans 9 states – Kerala, Tamil Nadu, Andhra Pradesh, Telangana, Karnataka, Maharashtra, Odisha, Gujarat, and West Bengal – as we move steadily towards establishing a pan-India footprint. The acquisition of Salem Erode Investments, a BSE-listed NBFC with a 93-year history in Tamil Nadu, has further reinforced our position in the financial sector. ICL Fincorp offers a comprehensive portfolio of services, including Gold Loans, Hire Purchase Loans and Business Loans. The ICL Group has also diversified into sectors such as travel, fashion, diagnostics and charitable initiatives. Under the joint leadership of CMD Adv. K.G. Anil Kumar and Mrs. Uma Anilkumar, Whole-time Director & CEO, ICL Fincorp, continues to operate in compliance with the Reserve Bank of India's standards, while earning the enduring trust of customers. As we unveil this new NCD issue, we warmly invite you to be a part of our journey towards financial growth, security and long-term value. (This is a press release and has not been vetted by our editorial team. All investments are subject to market risk. Do assess and decide.)

NSDL IPO allotment date next week; know how to check status online via PAN
NSDL IPO allotment date next week; know how to check status online via PAN

Indian Express

time6 hours ago

  • Indian Express

NSDL IPO allotment date next week; know how to check status online via PAN

NSDL IPO: Following the close of the subscription of initial public offering (IPO) of National Securities Depository Limited, all eyes of the investors will now be on the finalisation of the allotment of shares. The NSDL IPO allotment will take place next week. The NSDL IPO was opened on July 30 and concluded on August 1. The Rs 4,011-crore initial share sale got bids for 1,44,03,92,004 shares against 3,51,27,002 shares on offer, translating into 41.01 times subscription, as per NSE data, reports PTI. According to the PTI, NSDL IPO received 41 times subscription on the closing day of bidding. Qualified Institutional Buyers (QIBs) garnered 103.97 times subscription. The category for non-institutional investors received 34.98 times subscription and the portion for Retail Individual Investors (RIIs) got subscribed 7.73 times. NSDL has a price band of Rs 760 to Rs 800 per equity share. The NSDL IPO is likely to be finalised on August 4 (Monday). The allotment status will be released online on the official website of the registrar – MUFG Intime India Private Limited. Additionally, the allotment status will also be made available on the official website of the BSE. NSDL IPO Allotment Status Check on MUFG Intime India Private Limited – NSDL IPO Allotment Status Check on BSE Direct Link – NSDL shares are proposed to be listed on BSE. The listing will likely take place on August 6. This upcoming listing will make NSDL the country's second publicly traded depository after Central Depository Services (CDSL), which was listed on the NSE in 2017. (With inputs from PTI)

Mahindra & Mahindra acquires majority stake in SML Isuzu for Rs 555 cr
Mahindra & Mahindra acquires majority stake in SML Isuzu for Rs 555 cr

Economic Times

time6 hours ago

  • Economic Times

Mahindra & Mahindra acquires majority stake in SML Isuzu for Rs 555 cr

Agencies Mahindra & Mahindra SML Isuzu Mahindra & Mahindra (M&M) has acquired 58.96% controlling stake in SML Isuzu with a total investment of INR 555 crore. SML Isuzu Ltd. will be renamed to 'SML Mahindra Limited' after regulatory April 2025, M&M entered into an agreement to acquire a 58.96% equity stake in SML at Rs 650 per share, representing a total investment of Rs 555 crore."It is a big step for M&M towards establishing a strong presence in the >3.5T Commercial vehicles (CV) segment, where the company has a 3% market share presently, as compared to a 54.2% market share in the Sub-3.5 tonne LCV segment," the company acquisition is said to double the market share to 6%, with company's plan to increase this to 10% - 12% by FY31 and 20%+ by FY36. As part of the transaction, M&M would acquire the entire stake of 43.96% held by Sumitomo Corporation, promoter of SML, and separately also acquire 15% stake held by Isuzu Motors Ltd, for an aggregate consideration of INR 555 crore. M&M would also launch a mandatory open offer for acquisition of up to 26% stake from eligible public shareholders of SML in accordance with the SEBI Takeover Regulations. Mahindra & Mahindra Ltd. has appointed Vinod Sahay as Executive Chairman of SML Isuzu w.e.f. August 3 and Dr. Venkat Srinivas as the Executive Director & Chief Executive Officer of SML Isuzu Ltd w.e.f. from August Sahay will continue to serve as President – Aerospace & Defence, Trucks, Buses and Construction Equipment sector of Mahindra group in addition to his new role. Similarly, Dr. Venkat Srinivas will continue to serve as the Business Head for Mahindra Truck & Bus (MTB) and Construction Equipment (CE) in addition to this new role at SML Mahindra has a pan-India presence in the 'Trucks & Buses 'segment with 16% market share in ILCV (Intermediate and Light Commercial Vehicles) Buses segment. Shares of Mahindra & Mahindra Ltd. closed at Rs 3160.20 per unit on August 1 on BSE.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store